NanoViricides, Inc. (NNVC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Operating profit | $m | -10 | -8 | ||||||
| Net profit | $m | -13 | -9 | -8 | -9 | -8 | -9 | -8 | -6 |
| EPS reported | $ | -0.63 | -0.43 | ||||||
| Operating cashflow per share | $ | -0.56 | -0.34 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.56 | -0.34 | ||||||
| Free cash flow | $m | -9 | -7 | ||||||
| Net debt | $m | -2 | -3 | ||||||
| Book value equity | $m | 8 | 9 | ||||||
| Book value per share | $ | 0.50 | 0.42 | ||||||
| Number of shares | m | 15.12 | 21.61 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.82 | 2.31 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -2.48 | -2.87 | ||||||
| EV/EBITDA LTM | x | -2.25 | -2.60 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -44.73% | -27.13% | ||||||
| FCF Yield | % | -40.33% | -34.83% | ||||||
| Quality | |||||||||
| ROE | % | -125.93% | -92.69% | ||||||
| ROIC | % | -1.28% | -89.32% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.18 | 0.43 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.21 | -0.35 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free